...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019

"I don't understand why they use Alzheimers in this statement as we are ONLY testing VD and not Alzheimers"

As far as I know, there was no screening done for the 70+ year old patients to determine the specific type of cognitive disease. MoCA administered at baseline and annually for all patients 70 years or more. But no screening for presence or absence of Alzheimers, or requirement to only have vascular cognitive dementia, as far as I know. So there could be a mix of cognitive diseases in BETonMACE cognition sub-study.

BDAZ

Share
New Message
Please login to post a reply